Featured Content

Winston Wong, PharmD
President, W-Squared Group

The Punishing Cost of Cancer Care

(New York Times/Well blog) Dec 11, 2014 - As the price of chemotherapy now routinely reaches $100,000 for a full treatment course, my patients are forced more and more into making the equivalent of Sophie’s Choice when it comes to treating their cancer.

Commentary: This is becoming all too common a story. Even if ACA out-of-pocket caps apply, the maximum is still too high for...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Exclusive: Amgen's New Leukemia Drug to Carry $178,000 Price Tag

(Reuters) Dec 17, 2014 - Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs.
read article »

FDA Approves Lanreotide For Gastroenteropancreatic Tumors

(ASCO in Action) Dec 16, 2014 - On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline® Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
read article »

Solutions Needed to Stem Cancer Costs, ASH Experts Say

(Medscape Medical News) Dec 16, 2014 - In a special session at ASH, an expert panel discussed rising cancer costs, especially for new drugs, and the solutions needed to stem the tide while still offering quality care to patients.
read article (free registration required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



The Punishing Cost of Cancer Care (New York Times/Well blog)

This is becoming all too common a story. Even if ACA out-of-pocket caps apply, the maximum is still too high for...posted by: Winston Wong, PharmD

Mayo Clinic Physicians Say High-definition Scopes Accurately Assess Polyps, Costly Pathological Examinations May Not Be Necessary (Mayo Clinic)

So which will cost more...the HD evaluation or the pathologist.posted by: Winston Wong, PharmD

NanoString Technologies Highlights Important Results from Prosigna Decision Impact Study Presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (Reuters)

These are results that payers need to note. Payers are asking for studies like this, documenting that the results...posted by: Winston Wong, PharmD

340B: Serving Vulnerable Patients or Enriching Hospitals? (Medscape Medical News)

This is has been a concern for many years. We know 340B pricing existing in our contracted institutional facilities,...posted by: Winston Wong, PharmD

Through Len's Lens: Medicare and Lung Cancer Screening (Medpage Today)

Dr. Lichtenfeld, Deputy Chief Medical Officer of the American Cancer Society, is right to note that CMS is being...posted by: H. Jack West, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


NCCN has posted 1 new job.


Bayer Biopharmaceuticals, Inc. has posted 20 jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.


View OBR Job Board>>




The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
XNCR +29.58%
RDUS +17.76%
HALO +13.22%
PARD -29.17%
TLOG -3.59%
CRIS -2.61%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: January 3, 2015
Company: AstraZeneca PLC
Product: Lynparza™ (olaparib)

Date: Wed., January 7, 2015
Company: Sandoz Inc.
Product: EP2006

Date: February 22, 2015
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

See All OBR Radar items»